Address
21 Firstfield Road
Gaithersburg, MD 20878
United States of America (the)
Phone
240 268 2000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
952
First IPO Date
December 05, 1995
| Name | Title | Pay | Year Born |
| John Charles Jacobs | President, Chief Executive Officer & Director | 1.55M | 1967 |
| James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | 884,281 | 1966 |
| Elaine O'Hara | Executive Vice President & Chief Strategy Officer | 947,011 | 1968 |
| Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary | 984,255 | 1963 |
| Richard Crowley | Executive Vice President & Chief Operating Officer | 0 | 1957 |
| Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | 0 | 1971 |
| Erika S. Trahan | Associate Director of Investor & Public Relations | 0 | N/A |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | 0 | N/A |
| Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | 0 | 1963 |
| Luis Sanay | Vice President of Investor Relations | 0 | N/A |
| Robert Walker | EVice President and Head of Research & Development | 0 | N/A |
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.